You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CE

The Nurse View: Spotlight on Immune Checkpoint Inhibitors in Advanced Lung Cancer

  • Authors: Beth Eaby-Sandy, MSN, CRNP; Tammy Allred, RN, OCN; Emily Duffield, MPH, MSN, APRN
  • CE Released: 9/26/2018
  • THIS ACTIVITY HAS EXPIRED
  • Valid for credit through: 9/26/2019
Start Activity


Target Audience and Goal Statement

This activity is intended for nurses and nurse practitioners.

The goal of this activity is to provide perspective on where immune checkpoint inhibitors fit into treatment paradigms, as well as on monitoring and management strategies for immune-related adverse events (irAEs).

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the use of immune checkpoint inhibitors in advanced lung cancers
  • Have greater competence related to
    • Monitoring strategies for the timely identification of immune-related adverse events
    • Management of immune-related adverse events in patients with advanced lung cancers


Disclosures

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


Moderator

  • Beth Eaby-Sandy, MSN, CRNP

    Nurse Practitioner
    Abramson Cancer Center
    University of Pennsylvania
    Philadelphia, PA

    Disclosures

    Disclosure: Beth Eaby-Sandy, MSN, CRNP, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AbbVie Inc.
    Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Helsinn Therapeutics, Inc; Merck & Co., Inc.; Takeda Pharmaceuticals North America, Inc.

    Ms Eaby-Sandy does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Ms Eaby-Sandy does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Panelists

  • Tammy Allred, RN, OCN

    Oncology Nurse Navigator
    UNC Cancer Center
    Chapel Hill, NC

    Disclosures

    Disclosure: Tammy Allred, RN, OCN, has disclosed no relevant financial relationships.

    Ms Allred does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Ms Allred does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

  • Emily Duffield, MPH, MSN, APRN

    Advanced Practice Registered Nurse
    Smilow Cancer Hospital
    Yale New Haven Health
    Yale Cancer Center
    New Haven, CT

    Disclosures

    Disclosure: Emily Duffield, MPH, MSN, APRN, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP
    Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Merck & Co., Inc.; Pfizer Inc.

    Ms Duffield does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Ms Duffield does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Editor

  • Elaine Hamarstrom, PhD

    Scientific Director, Medscape, LLC

    Disclosures

    Disclosure: Elaine Hamarstrom, PhD, has disclosed no relevant financial relationships.

Course Director

  • Eileen Butler, RN, MSN, OCN, BMTCN

    Oncology Educator
    University Miami Hospitals and Clinics
    Sylvester Cancer Center
    Miami, Florida

    Disclosures

    Disclosure: Eileen Butler, RN, MSN, OCN, BMTCN has disclosed no relevant financial relationships.

SITC

  • Claire Leischer, MS

    Senior Manager of Online Education, Society for Immunotherapy of Cancer, Milwaukee, Wisconsin

    Disclosures

    Disclosure: Claire Leischer, MS, has disclosed no relevant financial relationships.

  • Erin Pacheco

    Program Manager, Society for Immunotherapy of Cancer, Milwaukee, Wisconsin

    Disclosures

    Disclosure: Erin Pacheco has disclosed no relevant financial relationships.

  • Alicia Schuessler, CAE

    Director of Education, Society for Immunotherapy of Cancer, Milwaukee, Wisconsin

    Disclosures

    Disclosure: Alicia Schuessler, CAE, has disclosed no relevant financial relationships.

  • Tara Withington, CAE

    Executive Director, Society for Immunotherapy of Cancer, Milwaukee, Wisconsin

    Disclosures

    Disclosure: Tara Withington has disclosed no relevant financial relationships.

Nurse Planner

  • Amy Bernard, MS, BSN, RN-BC, CHCP

    Lead Nurse Planner, Medscape, LLC

    Disclosures

    Disclosure: Amy Bernard, MS, BSN, RN-BC, CHCP, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.


Accreditation Statements




In support of improving patient care, this activity has been planned and implemented by Medscape, LLC and Society for Immunotherapy of Cancer. Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Nurses

  • Awarded 0.50 contact hour(s) of continuing nursing education for RNs and APNs; 0.50 contact hours are in the area of pharmacology.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CE

The Nurse View: Spotlight on Immune Checkpoint Inhibitors in Advanced Lung Cancer

Authors: Beth Eaby-Sandy, MSN, CRNP; Tammy Allred, RN, OCN; Emily Duffield, MPH, MSN, APRNFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED

CE Released: 9/26/2018

Valid for credit through: 9/26/2019

processing....

Educational Impact Challenge

The goal of this activity is to provide perspective on where immune checkpoint inhibitors fit into treatment paradigms, as well as on monitoring and management strategies for immune-related adverse events (irAEs).

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print